Cardiology

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).

Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.

A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.

Chronic hypertension in pregnancy was tied to 30% higher odds of critical congenital heart disease in a study of 44 million US births.

Ahmad Masri, MD, MS, highlights HCM agents to watch in 2027, including sotagliflozin and EDG-7500, and how MAPLE-HCM challenged beta-blocker use.

Ahmad Masri, MD, MS, discusses the move toward medical therapy in HCM, the nonobstructive treatment gap, and imaging's role in diagnosis and follow-up.

Low-frequency cannabis use was linked to 23% higher odds of self-reported cardiovascular disease and 40% higher odds of stroke in a BRFSS analysis.

Compared to metformin, GLP-1 RAs were linked to more normoglycemia reversion and less diabetes progression in 256,492 adults with prediabetes.

Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease.

Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.

Sebastian outlines a tiered carotid imaging strategy and the CTA findings pointing to dissection, vasculitis, or intraluminal thrombus.

Sebastian outlines why carotid webs, symptomatic non-stenotic carotid disease, and dissection can be missed when stroke workups focus on luminal narrowing.